• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Serbia Pharmaceuticals and Healthcare Report Q1 2013 - Product Image

Serbia Pharmaceuticals and Healthcare Report Q1 2013

  • ID: 2373659
  • January 2013
  • Region: Serbia
  • 100 pages
  • Business Monitor International

FEATURED COMPANIES

  • Company Monitor
  • Galenika
  • GlaxoSmithKline
  • Hemofarm (Stada)
  • Jugoremedija
  • Krka
  • MORE

BMI View:

While the market is small in terms of absolute numbers, relative per capita spending on medicines is expected to improve over the long term. As the country continues its economic convergence with developed Europe, drug consumption is also expected to rise. However, financial inefficiencies within the health insurance system mean that the National Health Insurance Institution (RZZO) is unable to always meet its obligations on time, leaving patients to pay for formerly reimbursed medicines or hospitals having to cover the difference.

Headline Expenditure Projections

- Pharmaceuticals: RSD75.70bn (US$1.03bn) in 2011 to RSD81.44bn (US$0.92bn) in 2012; +7.6% in local currency terms and -11.0% in US dollar terms.

- Healthcare: RSD347.71bn (US$4.74bn) in 2011 to RSD367.32bn (US$4.14bn) in 2012; +5.6% in local currency terms and -12.6% in US dollar terms.

- Medical devices: RSD16.64bn (US$223mn) in 2011 to RSD19.98bn (US$223mn) in 2012; +20.1
%in local currency terms and -0.7% in US dollar terms.

Risk/Reward Rating (RRR):

In BMI's RRR matrix for Q113, Serbia scored 44.7 and ranked 17th out of 20 pharmaceutical markets surveyed READ MORE >

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Company Monitor
  • Galenika
  • GlaxoSmithKline
  • Hemofarm (Stada)
  • Jugoremedija
  • Krka
  • MORE

Executive Summary 7

SWOT Analysis 9

Serbia Pharmaceuticals And Healthcare Industry SWOT 9

Serbia Political SWOT 10

Serbia Economic SWOT 10

Serbia Business Environment SWOT 11

Pharmaceutical Risk/Reward Ratings 12
Table: Emerging Europe Regional Pharma Risk/Reward Ratings For Q113 12

Rewards 13

Risks 13

Market Summary 15

Regulatory Regime 16
Table: The Number of Products On The Drugs List 16

Corruption In The Healthcare Sector 19

Intellectual Property Environment 21

Promotion 22

Pricing Regime 25

Price Developments 26

Reimbursement Regime 27
Table: Leading Suppliers Of Medicines To RZZO, By Value (RSDmn) 30
Table: Cost Of Prescriptions Covered By RZZO By Anatomical Therapeutic Chemical (ATC) Classification (RSD '000) 30

Industry Developments 31

Epidemiology 31

Communicable Diseases 31

Non-Communicable Diseases 32

Healthcare Sector 33
Table: Major General And Specialised Hospitals 35

Healthcare Insurance 36

Healthcare Debts 37

Clinical Trials 39

Medical Devices 40
Table: Medical Device Classification In Serbia 40

Industry Forecast Scenario 42

Overall Market Forecast 42
Table: Pharmaceutical Sales Indicators 2008-2016 43

Healthcare Market Forecast 44
Table: Healthcare Expenditure Indicators 2008-2016 45
Table: Healthcare Governmental Indicators 2008-2016 45
Table: Healthcare Private Indicators 2008-2016 46

Key Growth Factors - Macroeconomic 46
Table: Serbia - Economic Activity 50

Prescription Drug Market Forecast 50
Table: Prescription Drug Sales Indicators 2008-2016 51

Patented Drug Market Forecast 52
Table: Generic Drug Sales Indicators 2008-2016 53

Generic Drug Market Forecast 53
Table: Generic Drug Sales Indicators 2008-2016 54

OTC Medicine Market Forecast 55
Table: OTC Medicine Sales Indicators 2008-2016 56

Pharmaceutical Trade Forecast 56
Table: Exports Indicators 2008-2016 58
Table: Imports Indicators 2008-2016 58
Table: Trade Balance Indicators 2008-2016 59

Medical Device Market Forecast 59
Table: Medical Devices Sales Indicators 2008-2016 60

Other Healthcare Data Forecasts 60

Key Risks To BMI's Forecast Scenario 61

Competitive Landscape 62

Investment Climate 62

Pharmaceutical Industry 62
Table: Companies Involved In The Serbian Pharmaceutical Industry 63

Domestic Pharmaceutical Industry 64

Domestic Company Activity 65

Foreign Pharmaceutical Industry 66
Table: Proposed Members Of Serbia's Pharmaceutical Industry Association 67

Foreign Company Activity 68

Pharmaceutical Wholesale And Retail 68

Company Monitor 71

Indigenous Company Profiles 71

Hemofarm (Stada) 71

Galenika 74

Zdravlje Actavis (Watson + Actavis) 78

Jugoremedija 81

Multinational Company Profiles 83

Pfizer 83

GlaxoSmithKline 84

Novartis 85

Sanofi 86

Merck & Co 87

Krka 88

Demographic Outlook 90
Table: Serbia's Population By Age Group, 1990-2020 ('000) 91
Table: Serbia's Population By Age Group, 1990-2020 (% of total) 92
Table: Serbia's Key Population Ratios, 1990-2020 93
Table: Serbia's Rural And Urban Population, 1990-2020 93

Glossary 94

BMI Methodology 96

How We Generate Our Pharmaceutical Industry Forecasts 96

Pharmaceuticals Business Environment Ratings 97

Risk/Reward Ratings Methodology 97

Ratings System 97
Table: Pharmaceutical Business Environment Indicators 98

Weighting 99
Table: Weighting Of Components 99

Sources 99

Note: Product cover images may vary from those shown

Company Monitor
Indigenous Company Profiles
Hemofarm (Stada)
Galenika
Zdravlje Actavis (Watson + Actavis)
Jugoremedija
Multinational Company Profiles
Pfizer
GlaxoSmithKline
Novartis
Sanofi
Merck & Co
Krka

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos